Ever since Novo Nordisk entered the obesity market in 2015, its management and investors have hoped for another pharmaceutical firm to accompany it and help establishing and focusing on the market for relevant treatments.
"It's a challenge that we're actually the only company that's trying to create a market for the medical treatment of obesity," Novo Nordisk's Head of North America Operations and Executive Vice President Doug Langa has previously said.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.